Clinical Trial Update: Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating the effect of kidney impairment on exposure to idalopirdine (Lu AE58054) in subjects with and without renal dysfunction…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Idalopirdine (idalopirdine)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED